Allergic Conditions

New clinical data presented at EAACI Congress 2026 highlighted the continued evolution of hereditary angioedema (HAE) management. Alongside established long-term prophylactic and on-demand treatment strategies, investigational therapies are aiming to reduce treatment burden through oral formulations, longer dosing intervals and, potentially, one-time disease-modifying approaches. Here, we summarise some of the key HAE clinical trial updates presented at this year's meeting.

Non-advanced systemic mastocytosis (NonAdvSM) is a rare disease characterized by clonal mast cell accumulation across multiple organ systems. In this interview, Dr Nathan Boggs discusses the clinical burden of NonAdvSM and explores data from the Phase 2 SUMMIT trial (NCT05186753), presented at AAAAI 2026, which investigated bezuclastinib, an oral, selective KIT D816V inhibitor, for the treatment of NonAdvSM.

In this interview, Dr José Clemente discusses recent findings presented at AAAAI 2026 from the ACTIVATE trial, exploring whether modifying the early microbiome in Caesarean-delivered infants at risk of allergy can influence food sensitization and how early microbial exposures may shape immune development.

Omalizumab-facilitated multi-allergen oral immunotherapy (mOIT) is an established therapy for the treatment of food allergies. The COMBINE trial (NCT03679676) was a Phase 2 randomized controlled trial investigating whether adjunct dupilumab would improve patient outcomes with mOIT. In this Q&A, Dr Sayantani B. Sindher explores the established efficacy and safety profile of mOIT, the aims and methodology of the COMBINE trial, and the key findings and the implications they could have on clinical practice.

As 2025 draws to a close, we’re celebrating another remarkable year of growth, collaboration and innovation at touchIMMUNOLOGY. From thought-provoking expert interviews and peer-reviewed research to dynamic conference coverage and an expanding portfolio of medical education, this year has been defined by meaningful conversations and impactful learning. We’ve had the privilege of engaging with leading clinicians, researchers and partner societies across the globe - bringing together diverse voices to support the immunology community with timely, accessible and authoritative content. As we reflect on the past 12 months, we’re proud to highlight the moments, milestones and stories that shaped our year. Here are just some of the standout highlights from 2025.

Eosinophilic esophagitis (EoE) is a chronic, often debilitating condition that can significantly impact children’s growth and quality of life. Dupilumab, a fully human monoclonal antibody that inhibits IL-4 and IL-13 signaling, has emerged as a promising treatment option. In this Q&A, Dr Margaret H. Collins, a pathologist at Cincinnati Children’s Hospital, discusses the burden of pediatric EoE, the mechanism of action of dupilumab, and key findings from the phase 3 EoE KIDS trial, which demonstrated meaningful improvements in disease activity and a safety profile consistent with prior studies.

Dermatologists now have a new tool to transform the treatment landscape for patients living with chronic spontaneous urticaria (CSU): the first and only oral Bruton’s tyrosine kinase inhibitor (BTKi) approved by the FDA for this condition. This oral therapy is indicated for adults with CSU who remain symptomatic despite treatment with H1 antihistamines. Taken twice daily, it requires no injections or routine laboratory monitoring, offering a convenient and targeted option for patients whose symptoms persist on standard care.

Discover three breakthrough HAE treatments approved in 2025, offering new hope for hereditary angioedema care with improved prevention and treatment options.

In this episode, we speak with leading paediatric allergist Prof. Helen Brough to explore the key factors behind why some children develop allergies to foods such as peanuts, and what we can do to help prevent them. We also examine the latest developments in managing food allergies and the innovations on the horizon that could transform how we treat them.